Tag
Recent guideline updates elevate intravascular ultrasound (IVUS) and optical coherence tomography (OCT) from optional tools to Class I, Level A strategies for many complex percutaneous coronary interventions, driven by randomized trials and
ORBITA-FIRE shows that angina occurs at much lower, individualized FFR and RFR thresholds than standard ischemia cutoffs, and these thresholds rise with exercise intensity.
In women with chronic severe coronary artery disease, CABG was linked to lower long-term rates of death, stroke, heart attack, repeat revascularization, and cardiovascular readmission than PCI.
In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary int
ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guide
The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, st
The DKCRUSH VIII trial demonstrates that IVUS-guided PCI for complex coronary bifurcation lesions significantly reduces 1-year target vessel failure compared to angiography guidance, primarily by ensuring adherence to specific optimization
A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing
Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.
An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable wi
The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of t
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
A prespecified analysis of the REVIVED-BCIS2 trial reveals that baseline risk of death or hospitalization does not modify the effectiveness of PCI in patients with ischemic left ventricular dysfunction, reinforcing the primacy of optimal me
The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronar
Analysis of the PTRG-DES registry shows that platelet reactivity drives early ischemic risk post-PCI, while clinical risk factors (TRS2P) determine long-term prognosis, suggesting a need for temporally tailored secondary prevention strategi
A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.
In patients with acute coronary syndromes treated with PCI, stopping aspirin within 4 days and continuing potent P2Y12 inhibitor monotherapy reduced bleeding but did not meet noninferiority for ischemic events versus 12‑month DAPT; stent th
In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.
In low‑risk acute MI patients with early complete revascularization and 1 month of uneventful DAPT, stopping aspirin and continuing P2Y12‑inhibitor monotherapy was noninferior for ischemic outcomes and cut clinically relevant bleeding nearl
